← All trials
NCT05521984
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- May 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Aug 30, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Washington University in St. LouisLead sponsor
- Washington University in St. LouisCollaborator
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.